WallStreetZenWallStreetZen

NASDAQ: TLPH
Talphera Inc Stock Forecast, Predictions & Price Target

Analyst price target for TLPH

Based on 1 analyst offering 12 month price targets for Talphera Inc.
Min Forecast
$6.00+494.06%
Avg Forecast
$6.00+494.06%
Max Forecast
$6.00+494.06%

Should I buy or sell TLPH stock?

Based on 1 analyst offering ratings for Talphera Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their TLPH stock forecasts and price targets.

TLPH stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-07

1 of 1

Forecast return on equity

Is TLPH forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.72%

Forecast return on assets

Is TLPH forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

TLPH revenue forecast

What is TLPH's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$960.0k+47.47%
Avg 2 year Forecast
$10.4M+1,502.15%
Avg 3 year Forecast
$28.4M+4,265.59%
TLPH's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TLPH revenue growth forecast

How is TLPH forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?
Company
120.8%
Industry
9.09%
Market
10.27%
TLPH's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TLPH's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TLPH vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
TLPH$1.01$6.00+494.06%Buy
HUGE$0.46N/AN/A
FLGC$1.79$7.00+291.06%Strong Buy
AYTU$2.87N/AN/A
KALA$6.84$18.00+163.23%Buy

Talphera Stock Forecast FAQ

Is Talphera Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: TLPH) stock is to Buy TLPH stock.

Out of 1 analyst, 0 (0%) are recommending TLPH as a Strong Buy, 1 (100%) are recommending TLPH as a Buy, 0 (0%) are recommending TLPH as a Hold, 0 (0%) are recommending TLPH as a Sell, and 0 (0%) are recommending TLPH as a Strong Sell.

If you're new to stock investing, here's how to buy Talphera stock.

What is TLPH's revenue growth forecast for 2025-2027?

(NASDAQ: TLPH) Talphera's forecast annual revenue growth rate of 120.8% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.09%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.27%.

Talphera's revenue in 2024 is $651,000.On average, 1 Wall Street analysts forecast TLPH's revenue for 2025 to be $16,290,339, with the lowest TLPH revenue forecast at $16,290,339, and the highest TLPH revenue forecast at $16,290,339. On average, 1 Wall Street analysts forecast TLPH's revenue for 2026 to be $176,987,744, with the lowest TLPH revenue forecast at $176,987,744, and the highest TLPH revenue forecast at $176,987,744.

In 2027, TLPH is forecast to generate $482,261,907 in revenue, with the lowest revenue forecast at $482,261,907 and the highest revenue forecast at $482,261,907.

What is TLPH's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: TLPH) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of N/A.

What is TLPH's Price Target?

According to 1 Wall Street analyst that have issued a 1 year TLPH price target, the average TLPH price target is $6.00, with the highest TLPH stock price forecast at $6.00 and the lowest TLPH stock price forecast at $6.00.

The Wall Street analyst predicted that Talphera's share price could reach $6.00 by Mar 7, 2025. The average Talphera stock price prediction forecasts a potential upside of 494.06% from the current TLPH share price of $1.01.

What is TLPH's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: TLPH) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.